Osi Drug Patent Portfolio
Osi owns 1 orange book drug protected by 8 US patents Given below is the list of Osi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof | 09 May, 2021 | Expired |
| US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride | 09 May, 2021 | Expired |
| US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof | 09 Nov, 2020 | Expired |
| US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride | 09 Nov, 2020 | Expired |
| US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines | 08 May, 2019 | Expired |
| USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines | 08 May, 2019 | Expired |
| US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines | 08 Nov, 2018 | Expired |
| USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines | 08 Nov, 2018 | Expired |
Latest Legal Activities on Osi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Osi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2018 | US7087613 |
| Recordation of Patent Grant Mailed | 29 Dec, 2009 | USRE41065 |
| Issue Notification Mailed | 09 Dec, 2009 | USRE41065 |
| Receipt into Pubs | 07 Dec, 2009 | USRE41065 |
| Dispatch to FDC | 03 Dec, 2009 | USRE41065 |
| Application Is Considered Ready for Issue | 23 Nov, 2009 | USRE41065 |
| Issue Fee Payment Verified | 18 Sep, 2009 | USRE41065 |
| Issue Fee Payment Received | 18 Sep, 2009 | USRE41065 |
| Mail Notice of Allowance | 17 Sep, 2009 | USRE41065 |
| Notice of Allowance Data Verification Completed | 14 Sep, 2009 | USRE41065 |
| Case Docketed to Examiner in GAU | 14 Sep, 2009 | USRE41065 |
| Date Forwarded to Examiner | 23 Jul, 2009 | USRE41065 |
| Information Disclosure Statement considered | 07 Jul, 2009 | USRE41065 |
| Information Disclosure Statement (IDS) Filed | 07 Jul, 2009 | USRE41065 |
| Response after Non-Final Action | 07 Jul, 2009 | USRE41065 |
Osi's Drug Patent Litigations
Osi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 28, 2016, against patent number US6900221. The petitioner Apotex, Inc. et al., challenged the validity of this patent, with OSI Pharmaceuticals, LLC et al. as the respondent. Click below to track the latest information on how companies are challenging Osi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6900221 | June, 2016 |
Final Written Decision
(08 Jan, 2018)
| OSI Pharmaceuticals, LLC et al. | Apotex, Inc. et al. |
Osi's Family Patents
Osi Drug List
Given below is the complete list of Osi's drugs and the patents protecting them.
1. Tarceva
Tarceva is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900221
(Pediatric)
| Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
09 May, 2021
(4 years ago)
| Expired |
| US7087613
(Pediatric)
| Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
09 May, 2021
(4 years ago)
| Expired |
| US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
09 Nov, 2020
(5 years ago)
| Expired |
| US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
09 Nov, 2020
(5 years ago)
| Expired |
| US5747498
(Pediatric)
| Alkynyl and azido-substituted 4-anilinoquinazolines |
08 May, 2019
(6 years ago)
| Expired |
| USRE41065
(Pediatric)
| Alkynl and azido-substituted 4-anilinoquinazolines |
08 May, 2019
(6 years ago)
| Expired |
| US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines |
08 Nov, 2018
(7 years ago)
| Expired |
| USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines |
08 Nov, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tarceva's drug page